| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/24/2004 | US20040121965 Treating, inhibiting the growth of, or eradicating a tumor in a mammal in need thereof wherein tumor is resistant to at least one chemotherapeutic agent by providing to mammal an effective amount of a hemiasterlin compound |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121950 Drug comprising synthetic peptide analogs for the treatment of cancer |
| 06/24/2004 | US20040121940 Anticancer prodrugs, enhance enzymatic activation rates |
| 06/24/2004 | US20040121376 Antisense modulation of interleukin-5 signal transduction |
| 06/24/2004 | US20040121348 Compositions and methods for treating pancreatic cancer |
| 06/24/2004 | US20040121327 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040120994 polymer matrix contains the sex hormone testosterone and a mixture of a penetration-enhancing substance selected from fatty alcohol esters and fatty acid esters, and at least one readily volatile penetration-enhancing agent |
| 06/24/2004 | US20040120963 bacteria belongs to the genus Megasphaera or Mitsuokella |
| 06/24/2004 | US20040120954 expression of PEX without a catalytic site of MT1-MMP on a cell surface directly prevents an association of two enzymes and inhibits the activation of proMMP-2 in a dose-dependent manner |
| 06/24/2004 | US20040120952 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/24/2004 | US20040120948 antibody or a functional fragment thereof that recognizes a human CD40 antigen present on the surface of human B cells, dendritic cells |
| 06/24/2004 | US20040120935 Genetically modified yt cell line and use thereof |
| 06/24/2004 | US20040120928 Composite oncolytic herpes virus vectors |
| 06/24/2004 | US20040120896 Buccal aerosol sprays or capsules using polar and non-polar solvent which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect |
| 06/24/2004 | US20040120895 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 06/24/2004 | DE10258677A1 Combined use of antisense oligonucleotides for treating cancer, directed against the Polo-like kinase 1 and B cell leukemia/lymphoma 2 genes, having a synergistic effect |
| 06/24/2004 | DE10256182A1 2-Oxadiazolchromonderivate 2-Oxadiazolchromonderivate |
| 06/24/2004 | CA2509539A1 Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin .beta.c |
| 06/24/2004 | CA2508632A1 Dec-205 (ly 75) / dcl-1 intergenic splice variants associated with hodgkin's disease, and uses thereof |
| 06/24/2004 | CA2508020A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents |
| 06/24/2004 | CA2508010A1 3-phenyl-cinnoline analogue and antitumor agent using the same |
| 06/24/2004 | CA2508002A1 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| 06/24/2004 | CA2507137A1 Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents |
| 06/24/2004 | CA2506164A1 Anthranilic acid amide derivatives and their pharmaceutical use |
| 06/24/2004 | CA2506114A1 Cyanomethyl derivatives as cysteine protease inhibitors |
| 06/24/2004 | CA2505975A1 Ultrasound contrast using halogenated xanthenes |
| 06/23/2004 | EP1431311A1 Immunotherapy of B-cell malignancies using anti-CD22 and anti-CD20 antibodies in combination |
| 06/23/2004 | EP1431308A1 Enzyme phosphorylating ser46 of p53 |
| 06/23/2004 | EP1431290A1 Novel nitrogenous compound and use thereof |
| 06/23/2004 | EP1431286A2 Prodigiosin derivatives for treating cancer or viral diseases |
| 06/23/2004 | EP1431285A1 Reverse hydroxamic acid derivatives |
| 06/23/2004 | EP1431280A1 Aryl sulfamate derivatives |
| 06/23/2004 | EP1430934A1 Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 06/23/2004 | EP1430904A1 Desensitizers |
| 06/23/2004 | EP1430903A1 Use of proteasome inhibitors for the treatment of viral infections |
| 06/23/2004 | EP1430306A2 Method for predicting the sensitivity to chemotherapy |
| 06/23/2004 | EP1430302A2 Inhibitors of glycosaminoglycans |
| 06/23/2004 | EP1430157A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/23/2004 | EP1430152A2 Gene and protein relating to hepatocellular carcinoma |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430130A2 Nucleic acid-associated proteins |
| 06/23/2004 | EP1430129A2 Asip-related proteins |
| 06/23/2004 | EP1430128A2 Micro-rna molecules |
| 06/23/2004 | EP1430126A1 Dna sequences for human angiogenesis genes |
| 06/23/2004 | EP1430081A2 Brca1/acc alpha molecular complexes, diagnostic and therapeutic applications |
| 06/23/2004 | EP1430076A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 06/23/2004 | EP1430073A1 Solvent extraction process |
| 06/23/2004 | EP1430059A1 Pharmaceutically acceptable salts of 20(s)-camptothecins |
| 06/23/2004 | EP1430057A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives |
| 06/23/2004 | EP1430056A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 06/23/2004 | EP1430053A1 Chemical compounds |
| 06/23/2004 | EP1430051A1 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds |
| 06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 06/23/2004 | EP1430042A2 Bicyclic heterocycles as rxr ligands |
| 06/23/2004 | EP1430041A2 Novel sulfonic acid derivatives |
| 06/23/2004 | EP1430033A1 Anti-inflammatory and protein kinase inhibitor composition and method of use |
| 06/23/2004 | EP1430027A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 06/23/2004 | EP1430025A1 Methods and compositions for treating or preventing bacterial infection |
| 06/23/2004 | EP1430024A1 Alkyl urea retinoid agonists i |
| 06/23/2004 | EP1430023A1 Substituied urea retinoid agonists ii |
| 06/23/2004 | EP1430019A1 Sphingolipids |
| 06/23/2004 | EP1429844A2 Conjugated anti-psychotic drugs and uses thereof |
| 06/23/2004 | EP1429810A1 Transporting of taxoid derivatives through the blood brain barrier |
| 06/23/2004 | EP1429806A2 Extracellular massengers |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429796A2 Peptide antiangiogenic drugs |
| 06/23/2004 | EP1429784A2 High throughput screening assays using fatty acid synthetic enzymes |
| 06/23/2004 | EP1429782A1 Modulation of vitamin storage |
| 06/23/2004 | EP1429779A2 Androstanes as androgen receptor modulators |
| 06/23/2004 | EP1429778A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 06/23/2004 | EP1429773A1 Process for making substituted pyrazoles |
| 06/23/2004 | EP1429771A2 Bicyclic compounds as inhibitors of chemokine binding to us28 |
| 06/23/2004 | EP1429765A2 Inhibitors of histone deacetylase |
| 06/23/2004 | EP1429764A1 Compositions and methods for the treatment of cancer |
| 06/23/2004 | EP1429762A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| 06/23/2004 | EP1429761A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 06/23/2004 | EP1429756A2 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| 06/23/2004 | EP1429755A1 Use of vitamin e succinate and antiandrogen combination |
| 06/23/2004 | EP1429713A2 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
| 06/23/2004 | EP1429648A2 METHODS FOR SCREENING FOR SUBSTANCES WHICH INHIBIT FP PROSTANOID RECEPTOR INTERACTION WITH A COMPOUND HAVING PGF 2$g(a)alpha?ACTIVITY AND METHODS OF TREATING CANCER |
| 06/23/2004 | EP1265985A4 Pancreatic islet cell growth factors |
| 06/23/2004 | EP1255753B1 Prodigiosin-derivatives as neoplastic and anti-viral agents |
| 06/23/2004 | EP1252157B1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 06/23/2004 | EP1230227B1 Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors |
| 06/23/2004 | EP1214061B1 Use of docetaxel for treating hepatocellular carcinoma |
| 06/23/2004 | EP1214040A4 Extracts of orange peel for prevention and treatment of cancer |
| 06/23/2004 | EP1171573B1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 06/23/2004 | EP1165508B1 Anticancer calcium channel blockers |
| 06/23/2004 | EP1032671B1 Mammalian cytokine-like polypeptide-10 |
| 06/23/2004 | EP1024801B1 Method for regulating size and growth of vascularized normal tissue |
| 06/23/2004 | EP0930886B1 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv |
| 06/23/2004 | EP0779889B1 PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE |
| 06/23/2004 | EP0750505B1 Immunotherapy of cancer with allogeneic lymphocytes |
| 06/23/2004 | CN1507491A Apoptosis promoter and inhibitor interacting with CGI-94 and method of screening the same |
| 06/23/2004 | CN1507452A Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 06/23/2004 | CN1507450A Novel cyclo azaphospha hydrocarbons |
| 06/23/2004 | CN1507447A Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 06/23/2004 | CN1507444A 2,3-diazanaphthalene derivatives with angiogenesis inhibiting activity |